Its bookable profit will be almost €60 million (US$77.9 million), its chief financial officer and head of investor relations, Chris Tanner, told BioWorld International, as the company originally booked the shares at an average price of €1.77 per share
By Cormac Sheridan | BioWorld International | Wednesday, May 15, 2013
Its bookable profit will be almost €60 million (US$77.9 million), its chief financial officer and head of investor relations, Chris Tanner, told BioWorld Today, as the company originally booked the shares at an average price of €1.77 per share
By Cormac Sheridan | BioWorld Today | Wednesday, May 15, 2013
The cash infusion is the largest in Arrowhead's history – the firm pulled in $21 million in a 2006 funding round – and, at the current burn rate, should sustain operations into 2015, long enough to reach "critical catalyst events," said Vince Anzalone, director of finance and investor relations
By Jennifer Boggs | BioWorld Today | Tuesday, May 7, 2013
investor relations team in 2010 and meeting with a number of potential investors. (See BioWorld Today, March 20, 2013.) Net proceeds from the IPO are expected to total about $33.1 million – or $38.4 million if underwriters exercise their overallotment option in full
By Jennifer Boggs | BioWorld International | Wednesday, April 24, 2013
investor relations team in 2010 and meeting with a number of potential investors. (See BioWorld Today, March 20, 2013.) Net proceeds from the IPO are expected to total about $33
By Jennifer Boggs | BioWorld Today | Monday, April 22, 2013
We're challenging a decision of the EMA to disclose to a competitor parts of a document contained in our marketing authorization application for Esbriet," Jim Goff, vice president of corporate communications and investor relations, at Brisbane, Calif.-based InterMune told BioWorld International
BioWorld International | Wednesday, March 13, 2013
We're challenging a decision of the EMA to disclose to a competitor parts of a document contained in our marketing authorization application for Esbriet," Jim Goff, vice president of corporate communications and investor relations, at Brisbane, Calif.-based InterMune told BioWorld Today
By Cormac Sheridan | BioWorld Today | Tuesday, March 12, 2013
Andy Burrows, director of investor relations at BTG, told BioWorld Today that analysts are predicting "at least a $500 million increase in sales" as a result of the label extensions in the U.S
By Nuala Moran | BioWorld Today | Friday, December 14, 2012
Andy Burrows, director of investor relations at BTG, told BioWorld International that analysts are predicting "at least a $500 million increase in sales" as a result of the label extensions in the U.S
By Nuala Moran | BioWorld International | Wednesday, December 12, 2012
We understand it will be across multiple therapeutic areas," Richard Pye, head of investor relations and corporate communications at Oxford, UK-based Summit, told BioWorld Today
By Cormac Sheridan | BioWorld Today | Wednesday, September 12, 2012
We understand it will be across multiple therapeutic areas," Richard Pye, head of investor relations and corporate communications at Oxford, UK-based Summit, told BioWorld International
By Cormac Sheridan | BioWorld International | Wednesday, September 12, 2012
As of now, all options are being pursued, but senior director of investor relations, Laurie Doyle, was not in a position to comment on any merger or acquisition discussions that may be under way
By Cormac Sheridan | BioWorld International | Wednesday, August 29, 2012
As of now, all options are being pursued, but senior director of investor relations, Laurie Doyle, was not in a position to comment on any merger or acquisition discussions that may be under way
By Cormac Sheridan | BioWorld Today | Monday, August 27, 2012
Its bookable profit will be almost €60 million (US$77.9 million), its chief financial officer and head of investor relations, Chris Tanner, told BioWorld International, as the company originally booked the shares at an average price of €1.77 per share